Arguably, the concept of targeting SETD8 in cancer therapy gained significant momentum with a study published in 2017, where chemical and genetic screens converged to identify SETD8 as a specific vulnerability in High-Risk Neuroblastoma [9]. Here, KMT5A is linked to neuroblastoma.